{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:35:54Z","timestamp":1791549354326,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.tmaid.2020.101765","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T02:14:43Z","timestamp":1592273683000},"page":"101765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound"],"prefix":"10.1016","volume":"36","author":[{"given":"Suzan AM.","family":"Bouwman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rella","family":"Zoleko-Manego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin Csermak","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther K.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghyslain","family":"Mombo-Ngoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmaid.2020.101765_bib1","series-title":"World malaria report 2019","year":"2019"},{"key":"10.1016\/j.tmaid.2020.101765_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.micro.61.080706.093134","article-title":"Antigenic variation in Plasmodium falciparum","volume":"62","author":"Scherf","year":"2008","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.tmaid.2020.101765_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/1475-2875-13-463","article-title":"Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review","volume":"13","author":"Visser","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101765_bib4","article-title":"A research agenda for malaria eradication: drugs","volume":"8","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.tmaid.2020.101765_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101765_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084555","article-title":"How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs","author":"Bruxvoort","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.tmaid.2020.101765_bib8","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1021\/jm100410f","article-title":"Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria","volume":"53","author":"Yeung","year":"2010","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.tmaid.2020.101765_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/13543784.2015.1000483","article-title":"Antimalarial compounds in Phase II clinical development","volume":"24","author":"Held","year":"2015","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.tmaid.2020.101765_bib10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.12688\/f1000research.14874.1","article-title":"Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination","volume":"7","author":"Mathews","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.tmaid.2020.101765_bib11","unstructured":"https:\/\/www.novartis.com\/our-science\/novartis-global-pipeline?search_api_views_fulltext=malaria&field_pipeline_therapeutic_area [ ]=2616&field_pipeline_filing_date=All [last accessed 29 May 2020]."},{"key":"10.1016\/j.tmaid.2020.101765_bib12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.tmaid.2020.101765_bib13","first-page":"627806","article-title":"Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor","author":"Goldgof","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.tmaid.2020.101765_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2012.12.006","article-title":"Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials","volume":"13","author":"Spillman","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tmaid.2020.101765_bib15","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1074\/jbc.RA118.006706","article-title":"Characterization of the ATP4 ion pump in Toxoplasma gondii","volume":"294","author":"Lehane","year":"2019","journal-title":"J Biol Chem"},{"issue":"293","key":"10.1016\/j.tmaid.2020.101765_bib16","doi-asserted-by":"crossref","first-page":"13327","DOI":"10.1074\/jbc.RA118.003640","article-title":"Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes","volume":"24","author":"Rosling","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tmaid.2020.101765_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/infdis\/jiv358","article-title":"A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609","volume":"213","author":"Zhang","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101765_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00087-18","article-title":"Cell swelling induced by the antimalarial KAE609 (cipargamin) and other PfATP4-associated antimalarials","volume":"62","author":"Dennis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib19","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1128\/AAC.02838-15","article-title":"The spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasites","volume":"60","author":"Chavchich","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tmaid.2020.101765_bib20","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.06377-11","article-title":"The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector","volume":"56","author":"Van Pelt-Koops","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/AAC.03942-14","article-title":"Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tmaid.2020.101765_bib22","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1038\/s41598-017-16671-0","article-title":"Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission","volume":"15","author":"Dechering","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tmaid.2020.101765_bib23","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.3390\/molecules170910131","article-title":"Mechanistic study of the spiroindolones: a new class of antimalarials","volume":"17","author":"Zou","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.tmaid.2020.101765_bib24","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.accounts.7b00377","article-title":"Asymmetric cycloaddition and cyclization reactions catalyzed by chiral N, N\u2019-Dioxide\u2212Metal complexes","volume":"50","author":"Liu","year":"2017","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.tmaid.2020.101765_bib25","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1021\/acs.orglett.5b02300","article-title":"Stereoselective total synthesis of KAE609 via direct catalytic asymmetric alkynylation to ketimine","volume":"17","author":"Takada","year":"2015","journal-title":"Org Lett"},{"key":"10.1016\/j.tmaid.2020.101765_bib26","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1002\/anie.201505717","article-title":"Regio- and enantioselective aza-diels\u2013alder reactions of 3-vinylindoles: a concise synthesis of the antimalarial spiroindolone NITD609","volume":"54","author":"Zheng","year":"2015","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.tmaid.2020.101765_bib27","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1021\/acs.orglett.8b02335","article-title":"Synthesis of chiral tryptamines via a regioselective indole alkylation","volume":"20","author":"Wolfard","year":"2018","journal-title":"Org Lett"},{"key":"10.1016\/j.tmaid.2020.101765_bib28","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1002\/anie.201910008","article-title":"Enantioselective rhodium-catalyzed addition of arylboroxines to N-unprotected ketimines: efficient synthesis of cipargamin","volume":"58","author":"Zhu","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.tmaid.2020.101765_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1128\/AAC.03274-14","article-title":"Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model","volume":"59","author":"Lakshminarayana","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1124\/dmd.115.069112","article-title":"Identification of three novel ring expansion metabolites of KAE609, a new spiroindolone agent for the treatment of malaria, in rats, dogs, and humans","volume":"44","author":"Huskey","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tmaid.2020.101765_bib31","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1128\/AAC.03393-14","article-title":"A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers","volume":"58","author":"Leong","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.115.069187","article-title":"KAE609 (cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C] KAE609 in healthy male subjects","volume":"44","author":"Huskey","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tmaid.2020.101765_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2020.101765_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1258\/acb.2007.007167","article-title":"Interpreting indicators of iron status during an acute phase response \u2013 lessons from malaria and human immunodeficiency virus","volume":"45","author":"Northrop-Clewes","year":"2008","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.tmaid.2020.101765_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2125.1991.tb03904.x","article-title":"Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria","volume":"32","author":"Silamut","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.tmaid.2020.101765_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01940-16","article-title":"Estimation of the in vivo MIC of cipargamin in uncomplicated Plasmodium falciparum malaria","volume":"61","author":"Hien","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib37","unstructured":"Novartis Clinical trials results CKAE609X2202. An open label, single dose study to assess efficacy, safety, tolerability and pharmacokinetics of KAE609 in adult patients with acute, uncomplicated Plasmodium falciparum malaria mono-infection. https:\/\/www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=14013; [accessed 30 January 2020]."},{"key":"10.1016\/j.tmaid.2020.101765_bib39","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.17-0754","article-title":"The dynamics of liver function test abnormalities after malaria infection: a retrospective observational study","volume":"98","author":"Woodford","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101765_bib40","author":"gov"},{"key":"10.1016\/j.tmaid.2020.101765_bib41","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.19-0846","article-title":"Liver enzyme elevations in Plasmodium falciparum volunteer infection studies: findings and recommendations","author":"Chuglay","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101765_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ebiom.2018.09.018","article-title":"Liver injury in uncomplicated malaria is an overlooked phenomenon: an observational study","volume":"36","author":"Reuling","year":"2018","journal-title":"EBioMed"},{"key":"10.1016\/j.tmaid.2020.101765_bib43","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1128\/AAC.00340-15","article-title":"Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine","volume":"59","author":"Stein","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101765_bib44","author":"gov"},{"key":"10.1016\/j.tmaid.2020.101765_bib45","article-title":"Falciparum PfATP4 multi-drug resistance to KAE609 (cipargamin) is present in Africa","author":"Mc Culloch","year":"2018","journal-title":"Biorxiv"},{"key":"10.1016\/j.tmaid.2020.101765_bib46","unstructured":"WHO Evidence Review Group. The cardiotoxicity of antimalarials. Available at: http:\/\/www.who.int\/malaria\/mpac\/mpac-mar2017-erg-cardiotoxicity-report- session2-presentation.pdf?ua=1; [accessed 30 January 2020]."},{"key":"10.1016\/j.tmaid.2020.101765_bib47","series-title":"Eurartesim: summary of product characteristics","year":"2014"},{"key":"10.1016\/j.tmaid.2020.101765_bib48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiw128","article-title":"Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia","volume":"214","author":"Pasay","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101765_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tmaid.2017.12.005","article-title":"Abbreviated atovaquone-proguanil regimens in travellers after leaving malaria-endemic areas: a systematic review","volume":"21","author":"Savelkoel","year":"2018","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101765_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tmaid.2018.02.003","article-title":"Retrospective observational study of the use of artemether-lumefantrine in the treatment of malaria in Japan","volume":"22","author":"Nakamura-Uchiyama","year":"2018","journal-title":"Trav Med Infect Dis"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893920302532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893920302532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:04:46Z","timestamp":1761487486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893920302532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":48,"alternative-id":["S1477893920302532"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101765","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101765"}}